recombinant human activated protein C + hydrocortisone + fludrocortisone

This is a theoretical combination of three medications that have individually been studied for sepsis and septic shock. Recombinant human activated protein C (rhAPC, drotrecogin alfa) was previously used to reduce mortality in severe sepsis through its anticoagulant and potential anti-inflammatory properties. It works by inhibiting coagulation Factors Va and VIIIa. The combination of hydrocortisone and fludrocortisone has been shown to improve short-term survival in patients with septic shock compared to hydrocortisone alone or placebo. However, there is no evidence in the provided information that these three medications have been studied or used together as a single combination therapy.